Biota completes new flu trial
Thursday, 31 July, 2008
Biota Holdings [ASX: BTA] has completed the Phase II trials of its influenza treatment CS-8958, with Phase III trials set to commence later this year.
CS-8958 is a long-acting neuraminidase inhibitor [LANI], and is co-owned by Daiichi-Sankyo.
Several hundred flu patients participated in the double-blind trial, which was conducted to the standards of the Japanese Pharmaceuticals and Medical Devices Agency.
The trial revealed that one dose of CS-8958 produced results indistinguishable from 75mg of oseltamivir administered twice daily for five days.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
